Latest Breaking News On - Halsin partners - Page 4 : comparemela.com

Addex Announces Participation in the H C Wainwright 25th

Geneva, Switzerland, September 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric.

United statesNew yorkTim dyerMike sinclairSwiss exchangeChief executive officerAnnual global investment conferenceAddex therapeuticsAmerican depositary sharesExecutive officerHalsin partnersSwiss stock exchange adxnAddex therapeutics

Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024 -Today at 01:01 am

Cohort 1 is completed, and Cohort 2 is 80% recruited Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 5, 2023 - Addex Therapeutics , a clinical-stage pharmaceutical company.

United statesMike sinclairTim dyerJanssen pharmaceuticals incJanssen pharmaceutical companies of johnsonSwiss exchangeHoc announcement pursuantJanssen pharmaceuticalsJanssen pharmaceutical companiesInterim review committeeAddex therapeuticsAmerican depositary sharesExecutive officerHalsin partnersForward looking statementsPrivate securities litigation reform act

Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024

Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesMike sinclairTim dyerJanssen pharmaceutical companies of johnsonJanssen pharmaceuticals incSwiss exchangeHoc announcement pursuantAddex therapeuticsJanssen pharmaceuticalsJanssen pharmaceutical companiesInterim review committeeAmerican depositary sharesExecutive officerHalsin partners

Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout

Cohort 1 is completed, and Cohort 2 is 80% recruited Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 5, 2023 - Addex.

United statesMike sinclairTim dyerSwiss exchangeJanssen pharmaceutical companies of johnsonJanssen pharmaceuticals incHoc announcement pursuantJanssen pharmaceuticalsJanssen pharmaceutical companiesInterim review committeeAddex therapeuticsAmerican depositary sharesExecutive officerHalsin partnersSwiss stock exchange adxnAddex therapeutics

Addex s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain

Landmark study shows mGlu5 receptor negative allosteric modulators (NAMs) restore lost neurological functionsFirst time mGlu5 linked to post-strok.

United statesTim dyerMike sinclairMikhail kalinichevJanssen pharmaceuticals incSwiss exchangeHoc announcement pursuantTranslational scienceAddex therapeuticsJanssen pharmaceuticalsAmerican depositary sharesExecutive officerHalsin partnersForward looking statementsPrivate securities litigation reform actAddex therapeutic annual report